$656 Million is the total value of Bellevue Asset Management AG's 127 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | UnitedHealth Group Incorporated | $14,117,000 | +1.4% | 120,000 | 0.0% | 2.15% | -5.3% | |
| SYK | Stryker Corporation | $13,077,000 | -1.2% | 140,700 | 0.0% | 1.99% | -7.8% | |
| EARS | Auris Medical Holding AG | $10,414,000 | +34.8% | 2,169,625 | 0.0% | 1.59% | +26.0% | |
| ZBH | Zimmer Holdings, Inc. | $9,797,000 | +9.2% | 95,500 | 0.0% | 1.49% | +2.1% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $9,423,000 | +22.0% | 49,400 | 0.0% | 1.44% | +14.0% | |
| STJ | St. Jude Medical, Inc. | $7,536,000 | -2.1% | 122,000 | 0.0% | 1.15% | -8.5% | |
| BMRN | BioMarin Pharmaceutical Inc. | $6,809,000 | -0.5% | 65,000 | 0.0% | 1.04% | -7.2% | |
| AET | Aetna Inc. | $5,730,000 | -1.2% | 53,000 | 0.0% | 0.87% | -7.7% | |
| HUM | Humana, Inc. | $5,355,000 | -0.3% | 30,000 | 0.0% | 0.82% | -6.8% | |
| JNJ | Johnson & Johnson | $5,136,000 | +10.0% | 50,000 | 0.0% | 0.78% | +2.9% | |
| ACHN | Achillion Pharmaceuticals, Inc. | $4,532,000 | +56.2% | 420,000 | 0.0% | 0.69% | +46.1% | |
| ANTM | Anthem, Inc. | $4,183,000 | -0.4% | 30,000 | 0.0% | 0.64% | -7.0% | |
| BMY | Bristol-Myers Squibb Company | $4,127,000 | +16.2% | 60,000 | 0.0% | 0.63% | +8.6% | |
| NBIX | Neurocrine Biosciences, Inc. | $3,677,000 | +42.2% | 65,000 | 0.0% | 0.56% | +32.7% | |
| AGIO | Agios Pharmaceuticals, Inc. | $3,506,000 | -8.0% | 54,000 | 0.0% | 0.53% | -14.1% | |
| NVDQ | Novadaq Technologies Inc. | $3,185,000 | +22.1% | 250,000 | 0.0% | 0.48% | +14.1% | |
| MRK | Merck & Co., Inc. | $3,169,000 | +7.0% | 60,000 | 0.0% | 0.48% | 0.0% | |
| HOLX | Hologic, Inc. | $3,134,000 | -1.1% | 81,000 | 0.0% | 0.48% | -7.5% | |
| MASI | Masimo Corporation | $3,113,000 | +7.6% | 75,000 | 0.0% | 0.47% | +0.4% | |
| ARIA | ARIAD Pharmaceuticals, Inc. | $3,094,000 | +7.0% | 495,000 | 0.0% | 0.47% | -0.2% | |
| VAR | Varian Medical Systems, Inc. | $2,990,000 | +9.5% | 37,000 | 0.0% | 0.46% | +2.5% | |
| LLY | Lilly Eli & Co. | $2,949,000 | +0.7% | 35,000 | 0.0% | 0.45% | -6.1% | |
| TMO | Thermo Fisher Scientific Inc. | $2,837,000 | +16.0% | 20,000 | 0.0% | 0.43% | +8.3% | |
| NVAX | Novavax, Inc. | $2,727,000 | +18.7% | 325,000 | 0.0% | 0.42% | +10.9% | |
| MGNX | Macrogenics, Inc. | $2,571,000 | +44.6% | 83,000 | 0.0% | 0.39% | +35.2% | |
| CLDX | Celldex Therapeutics, Inc. | $2,509,000 | +48.8% | 160,000 | 0.0% | 0.38% | +38.9% | |
| COO | Cooper Companies Inc. | $2,483,000 | -9.8% | 18,500 | 0.0% | 0.38% | -15.8% | |
| TFX | Teleflex Incorporated | $2,439,000 | +5.8% | 18,557 | 0.0% | 0.37% | -1.1% | |
| GMED | Globus Medical, Inc.cl a | $2,440,000 | +34.7% | 87,700 | 0.0% | 0.37% | +25.7% | |
| NUVA | Nuvasive, Inc. | $2,435,000 | +12.2% | 45,000 | 0.0% | 0.37% | +4.8% | |
| HCSG | Healthcare Services Group Inc. | $2,267,000 | +3.5% | 65,000 | 0.0% | 0.34% | -3.4% | |
| INO | Inovio Pharmaceuticals, Inc. | $1,781,000 | +16.3% | 265,000 | 0.0% | 0.27% | +8.4% | |
| WCG | WellCare Health Plans, Inc. | $1,564,000 | -9.3% | 20,000 | 0.0% | 0.24% | -15.3% | |
| UTHR | United Therapeutics Corporation | $1,456,000 | +19.2% | 9,300 | 0.0% | 0.22% | +11.6% | |
| DVA | Davita Healthcare Partners, Inc. | $1,394,000 | -3.7% | 20,000 | 0.0% | 0.21% | -10.2% | |
| LH | Laboratory Corporation of America Holdings | $1,236,000 | +13.9% | 10,000 | 0.0% | 0.19% | +6.2% | |
| ANGO | AngioDynamics, Inc. | $1,214,000 | -8.0% | 100,000 | 0.0% | 0.18% | -14.0% | |
| ESPR | Esperion Therapeutics Inc. | $890,000 | -5.7% | 40,000 | 0.0% | 0.14% | -11.7% | |
| IBB | Ishares TRnasdq biotec etf | $846,000 | +11.6% | 2,500 | 0.0% | 0.13% | +4.0% | |
| AFFX | Affymetrix, Inc. | $807,000 | +18.2% | 80,000 | 0.0% | 0.12% | +10.8% | |
| RMD | ResMed Inc. | $805,000 | +5.4% | 15,000 | 0.0% | 0.12% | -1.6% | |
| IPXL | Impax Laboratories, Inc. | $770,000 | +21.5% | 18,000 | 0.0% | 0.12% | +13.6% | |
| TMH | Team Health Holdings Inc. | $658,000 | -18.8% | 15,000 | 0.0% | 0.10% | -24.2% | |
| ABUS | Arbutus Biopharm Corporation | $556,000 | -26.9% | 125,000 | 0.0% | 0.08% | -31.5% | |
| JNP | Juniper Pharmaceuticals Inc. | $515,000 | -12.6% | 50,000 | 0.0% | 0.08% | -18.8% | |
| CSII | Cadiovascular Systems Inc. | $454,000 | -4.4% | 30,000 | 0.0% | 0.07% | -10.4% | |
| MNKD | MannKind Corporation | $435,000 | -54.8% | 300,000 | 0.0% | 0.07% | -58.0% | |
| IMGN | Immunomedics, Inc. | $407,000 | +41.3% | 30,000 | 0.0% | 0.06% | +31.9% | |
| XOMA | XOMA Corporation | $299,000 | +76.9% | 225,000 | 0.0% | 0.05% | +64.3% | |
| TTPH | Tetraphase Pharmaceuticals, Inc. | $221,000 | +34.8% | 22,000 | 0.0% | 0.03% | +25.9% | |
| GERN | Geron Corporation | $218,000 | +75.8% | 45,000 | 0.0% | 0.03% | +65.0% | |
| TBPH | Theravance Biopharma, Inc. | $187,000 | +48.4% | 11,428 | 0.0% | 0.03% | +33.3% | |
| CLDN | Celladon Corporation | $74,000 | +39.6% | 50,000 | 0.0% | 0.01% | +22.2% | |
| AST | Asterias Biotherapeutics, Inc. | $7,000 | 0.0% | 1,875 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biogen Inc. | 4 | Q4 2015 | 4.2% |
| Celgene Corporation | 4 | Q4 2015 | 4.1% |
| Gilead Sciences, Inc. | 4 | Q4 2015 | 4.1% |
| Medtronic, Inc. | 4 | Q4 2015 | 3.7% |
| Abbott Laboratories | 4 | Q4 2015 | 3.3% |
| Regeneron Pharmaceuticals, Inc. | 4 | Q4 2015 | 3.0% |
| Amgen Inc. | 4 | Q4 2015 | 3.0% |
| Illumina, Inc. | 4 | Q4 2015 | 2.7% |
| UnitedHealth Group Incorporated | 4 | Q4 2015 | 2.3% |
| Stryker Corporation | 4 | Q4 2015 | 2.2% |
View Bellevue Asset Management AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Auris Medical Holding AG | February 14, 2018 | 2,169,625 | 4.5% |
View Bellevue Asset Management AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-14 |
| 13F-NT | 2023-08-14 |
| 13F-NT | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-11 |
| 13F-NT | 2022-05-13 |
| 13F-NT | 2022-02-10 |
| 13F-NT | 2021-11-12 |
View Bellevue Asset Management AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.